Abstract
Background: Advanced glycation endproducts (AGES) predict long-term complications in age-related diseases. However, there are no clinically applicable markers for measuring AGES in vivo.
Methods: We have recently introduced the AGE-Reader (DiagnOptics B.V., Groningen, The Netherlands) to noninvasively measure AGE accumulation in the human skin of the forearm, making use of the characteristic autofluorescence (AF) pattern that AGES encompass. Skin AF is calculated as a ratio of mean intensities detected from the skin between 420-600 nm. and 300-420 nm. It correlates with collagen-linked fluorescence and specific skin AGE levels from skin biopsies in diabetes, renal failure, and control subjects. Skin AF levels are increased in patients with diabetes and renal failure and are associated with the presence of vascular complications. Additionally, skin AF is strongly related to the progression of coronary heart disease and mortality, independently of traditional risk factors. Since skin pigmentation might influence skin AF, we have investigated the relation of relative skin reflectance (R%) to skin AF in subjects with varying skin phototypes (SPT).
Results: The data presented in this article suggest that only in subjects with an SPT of V and VI or R% 12%, and more research is needed for a broader application.
Conclusion: The AGE-Reader is useful as a noninvasive clinical tool for assessment of risk for long-term vascular complications in diabetes and in other conditions associated with AGE accumulation.
Original language | English |
---|---|
Pages (from-to) | 523-535 |
Number of pages | 13 |
Journal | |
Volume | 8 |
Issue number | 5 |
DOIs | |
Publication status | Published - Oct-2006 |
Keywords
- GLYCOSYLATION END-PRODUCTS
- COLLAGEN-LINKED FLUORESCENCE
- DEPENDENT DIABETES-MELLITUS
- MAILLARD REACTION-PRODUCTS
- HEMODIALYSIS-PATIENTS
- SOLUBLE RECEPTOR
- NONDIABETIC MEN
- PLASMA-LEVELS
- SERUM-LEVELS
- AGE
Access to Document
Skin Autofluorescence, a Novel Marker for Glycemic and Oxidative Stress-Derived Advanced Glycation EndproductsFinal publisher's version, 244 KBLicence: Unspecified
Handle.net
Fingerprint
Dive into the research topics of 'Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: An overview of current clinical studies, evidence, and limitations'. Together they form a unique fingerprint.
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
Mulder, D. J., Van de Water, T., Lutgers, H. L., Graaff, R., Gans, R. O., Zijlstra, F. (2006). Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: An overview of current clinical studies, evidence, and limitations. , 8(5), 523-535. https://doi.org/10.1089/dia.2006.8.523
Mulder, Douwe J. ; Van de Water, Tara ; Lutgers, Helen L. et al. / Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts : An overview of current clinical studies, evidence, and limitations. In: . 2006 ; Vol. 8, No. 5. pp. 523-535.
@article{dae596c0cfbf4cc998c3c68bc2f05a63,
title = "Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: An overview of current clinical studies, evidence, and limitations",
abstract = "Background: Advanced glycation endproducts (AGES) predict long-term complications in age-related diseases. However, there are no clinically applicable markers for measuring AGES in vivo.Methods: We have recently introduced the AGE-Reader (DiagnOptics B.V., Groningen, The Netherlands) to noninvasively measure AGE accumulation in the human skin of the forearm, making use of the characteristic autofluorescence (AF) pattern that AGES encompass. Skin AF is calculated as a ratio of mean intensities detected from the skin between 420-600 nm. and 300-420 nm. It correlates with collagen-linked fluorescence and specific skin AGE levels from skin biopsies in diabetes, renal failure, and control subjects. Skin AF levels are increased in patients with diabetes and renal failure and are associated with the presence of vascular complications. Additionally, skin AF is strongly related to the progression of coronary heart disease and mortality, independently of traditional risk factors. Since skin pigmentation might influence skin AF, we have investigated the relation of relative skin reflectance (R%) to skin AF in subjects with varying skin phototypes (SPT).Results: The data presented in this article suggest that only in subjects with an SPT of V and VI or R% 12%, and more research is needed for a broader application.Conclusion: The AGE-Reader is useful as a noninvasive clinical tool for assessment of risk for long-term vascular complications in diabetes and in other conditions associated with AGE accumulation.",
keywords = "GLYCOSYLATION END-PRODUCTS, COLLAGEN-LINKED FLUORESCENCE, DEPENDENT DIABETES-MELLITUS, MAILLARD REACTION-PRODUCTS, HEMODIALYSIS-PATIENTS, SOLUBLE RECEPTOR, NONDIABETIC MEN, PLASMA-LEVELS, SERUM-LEVELS, AGE",
author = "Mulder, {Douwe J.} and {Van de Water}, Tara and Lutgers, {Helen L.} and Reindert Graaff and Gans, {Rijk O.} and Felix Zijlstra and Smit, {Andries J.}",
year = "2006",
month = oct,
doi = "10.1089/dia.2006.8.523",
language = "English",
volume = "8",
pages = "523--535",
journal = "Diabetes technology & therapeutics",
issn = "1520-9156",
publisher = "MARY ANN LIEBERT, INC",
number = "5",
}
Mulder, DJ, Van de Water, T, Lutgers, HL, Graaff, R, Gans, RO, Zijlstra, F 2006, 'Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: An overview of current clinical studies, evidence, and limitations', , vol. 8, no. 5, pp. 523-535. https://doi.org/10.1089/dia.2006.8.523
Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: An overview of current clinical studies, evidence, and limitations. / Mulder, Douwe J.; Van de Water, Tara; Lutgers, Helen L. et al.
In: , Vol. 8, No. 5, 10.2006, p. 523-535.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts
T2 - An overview of current clinical studies, evidence, and limitations
AU - Mulder, Douwe J.
AU - Van de Water, Tara
AU - Lutgers, Helen L.
AU - Graaff, Reindert
AU - Gans, Rijk O.
AU - Zijlstra, Felix
AU - Smit, Andries J.
PY - 2006/10
Y1 - 2006/10
N2 - Background: Advanced glycation endproducts (AGES) predict long-term complications in age-related diseases. However, there are no clinically applicable markers for measuring AGES in vivo.Methods: We have recently introduced the AGE-Reader (DiagnOptics B.V., Groningen, The Netherlands) to noninvasively measure AGE accumulation in the human skin of the forearm, making use of the characteristic autofluorescence (AF) pattern that AGES encompass. Skin AF is calculated as a ratio of mean intensities detected from the skin between 420-600 nm. and 300-420 nm. It correlates with collagen-linked fluorescence and specific skin AGE levels from skin biopsies in diabetes, renal failure, and control subjects. Skin AF levels are increased in patients with diabetes and renal failure and are associated with the presence of vascular complications. Additionally, skin AF is strongly related to the progression of coronary heart disease and mortality, independently of traditional risk factors. Since skin pigmentation might influence skin AF, we have investigated the relation of relative skin reflectance (R%) to skin AF in subjects with varying skin phototypes (SPT).Results: The data presented in this article suggest that only in subjects with an SPT of V and VI or R% 12%, and more research is needed for a broader application.Conclusion: The AGE-Reader is useful as a noninvasive clinical tool for assessment of risk for long-term vascular complications in diabetes and in other conditions associated with AGE accumulation.
AB - Background: Advanced glycation endproducts (AGES) predict long-term complications in age-related diseases. However, there are no clinically applicable markers for measuring AGES in vivo.Methods: We have recently introduced the AGE-Reader (DiagnOptics B.V., Groningen, The Netherlands) to noninvasively measure AGE accumulation in the human skin of the forearm, making use of the characteristic autofluorescence (AF) pattern that AGES encompass. Skin AF is calculated as a ratio of mean intensities detected from the skin between 420-600 nm. and 300-420 nm. It correlates with collagen-linked fluorescence and specific skin AGE levels from skin biopsies in diabetes, renal failure, and control subjects. Skin AF levels are increased in patients with diabetes and renal failure and are associated with the presence of vascular complications. Additionally, skin AF is strongly related to the progression of coronary heart disease and mortality, independently of traditional risk factors. Since skin pigmentation might influence skin AF, we have investigated the relation of relative skin reflectance (R%) to skin AF in subjects with varying skin phototypes (SPT).Results: The data presented in this article suggest that only in subjects with an SPT of V and VI or R% 12%, and more research is needed for a broader application.Conclusion: The AGE-Reader is useful as a noninvasive clinical tool for assessment of risk for long-term vascular complications in diabetes and in other conditions associated with AGE accumulation.
KW - GLYCOSYLATION END-PRODUCTS
KW - COLLAGEN-LINKED FLUORESCENCE
KW - DEPENDENT DIABETES-MELLITUS
KW - MAILLARD REACTION-PRODUCTS
KW - HEMODIALYSIS-PATIENTS
KW - SOLUBLE RECEPTOR
KW - NONDIABETIC MEN
KW - PLASMA-LEVELS
KW - SERUM-LEVELS
KW - AGE
U2 - 10.1089/dia.2006.8.523
DO - 10.1089/dia.2006.8.523
M3 - Article
C2 - 17037967
SN - 1520-9156
VL - 8
SP - 523
EP - 535
JO - Diabetes technology & therapeutics
JF - Diabetes technology & therapeutics
IS - 5
ER -
Mulder DJ, Van de Water T, Lutgers HL, Graaff R, Gans RO, Zijlstra F et al. Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: An overview of current clinical studies, evidence, and limitations. . 2006 Oct;8(5):523-535. doi: 10.1089/dia.2006.8.523